Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRYZ-T101 for HPV18 Positive Advanced Solid Tumors
NCT05787535Phase 1Recruiting
- Sponsor
- HRYZ Biotech
- Start
- Mar 2023
- Primary completion
- Feb 2025
- Modality
- TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HRYZ-T101 in Cervical Cancer (CC), head and neck squamous cell carcinoma (HNSCC), oropharyngeal cancer and 4 more, sponsored by HRYZ Biotech. Primary endpoints: Dose Limiting Toxicity at 28 days and Adverse Events at 2 years. Started Mar 2023; status: recruiting.
02
Drugs
HRYZ-T101
03
Conditions
Cervical Cancer (CC)head and neck squamous cell carcinoma (HNSCC)oropharyngeal cancervaginal cancerpenile cancer
Beyond the preview
Go deeper on NCT05787535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05787535.